Daily Schedule - Sunday - September 21

Continental Breakfast
7:00 a.m.-8:00 a.m.

Plenary Session 1: Tumor Microenvironment and Metabolism
Session Chairperson: Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Mass.
*Please note: Dr. John Gribben is unable to attend.
8:00 a.m.-10:00 a.m.

Mouse models of isocitrate dehydrogenase (IDH) mutations in hematologic malignancies
Tak W. Mak, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, Ont., Canada

Patient Advocate
Jack Whelan,

Multiple myeloma as a model of bone metastasis
Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Mass.

The microenvironment in CLL: Cellular and molecular players and emerging therapeutic targets
Jan A. Burger, The University of Texas MD Anderson Cancer Center, Houston, Texas


10:00 a.m.-10:30 a.m.

Plenary Session 2: Immunotherapy
Session Chairperson: Ronald Levy, Stanford University, Stanford, Calif.
10:30 a.m.-12:30 p.m.

CARs for leukemia and beyond?
Carl H. June, Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pa.

Monoclonal antibodies and in situ vaccination
Ronald Levy

Developing broadly active immunotherapy
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, Mass.

Pre-clinical development of a humanized anti-CD47 antibody targeting AML stem cells
Ravindra Majeti, Stanford School of Medicine, Stanford, Calif.

12:30 p.m.-1:00 p.m.

Panel Discussion 1: Drug Development in the 21st Century: Tackling the Grand Challenges
1:00 p.m.-2:30 p.m.
Session Chairperson: Wyndham E. Wilson, National Cancer Institute, Bethesda, Md.

Wyndham H. Wilson

Richard B. Gaynor, Eli Lilly and Company, Indianapolis, Ind.

Michael J. Keating, The University of Texas MD Anderson Cancer Center, Houston, Texas

James L. Omel, Central Nebraska Multiple Myeloma Support Group, Grand Island, Neb.

Poster Session A with Light Refreshments
2:30 p.m.-5:00 p.m.

Joint Session with AACR Melanoma Special Conference
Clinical Science Intersections between Melanoma and Hematologic Malignancies
5:00 p.m.-7:30 p.m.
Two hematology experts will be joined by two speakers from the AACR Special Conference on Advances in Melanoma: From Biology to Therapy to create a unique session and an opportunity to interact with colleagues across disciplines. Overlapping themes in solid and blood cancers will be discussed in the areas of signaling, targeted therapy, and immunotherapy.
Introduction by Session Chairpersons
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, Mass.

MRA: Powerful research, Faster results
Wendy K.D. Selig, President and CEO, Melanoma Research Alliance, Washington, D.C.

Research: Moving beyond hope to outcomes
Elizabeth Thompson, CEO, Lymphoma Research Foundation, New York, N.Y.

Preclinical models for targeting oncogenic Ras signaling in cancer

Kevin M. Shannon, University of California, San Francisco, Calif.

Treatment of non-V600- mutated BRAF melanoma: A role for combination MEK and CDK4/6 inhibition
Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, Tenn.

PD-1 pathway immunotherapy
Gordon Freeman, Dana-Farber Cancer Institute, Boston, Mass.

Adoptive T-cell therapy with CAR-modified T-cells: We have a Model A Ford—can we build a Ferrari?
Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, N.Y.


Reception for the attendees of both AACR Special Conferences
7:30 p.m.-9:00 p.m.